Milwaukee Bucks' Damian Lillard is sidelined due to deep vein thrombosis (DVT) in his right calf, as announced by the team. Initially missing three games with a calf strain, doctors later identified a blood clot. Lillard is now on blood-thinning medication, which has dissolved the clot. He will undergo regular testing to ensure safe return to play.
The Bucks' general manager, Jon Horst, emphasized that "Damian's health is our No. 1 priority." He assured support for Lillard during his recovery process, which involves strict criteria for his return. Doctors believe this condition is unlikely to recur. Quick identification and treatment have aided Lillard's recovery.

Lillard's absence poses a significant challenge for the Bucks. They are currently the fifth seed in the Eastern Conference, aiming for home-court advantage against the Indiana Pacers in the playoffs. His performance this season showed improvement over last year, with better stats across various categories.
Despite uncertainty about Lillard's return this season, his absence is a setback for Milwaukee. The team might face another playoff without a key player after Giannis Antetokounmpo missed last year's first-round loss to Indiana Pacers.
DVT can be severe if untreated, risking pulmonary embolism or stroke. Blood thinners help prevent further clots but increase bleeding risks, complicating matters for athletes. The situation mirrors San Antonio Spurs' Victor Wembanyama's case, who missed the season due to DVT in his shoulder.
Lillard was recently selected for his 10th All-Star game and ranks 11th in NBA scoring with an average of 24.9 points per game this season. His improved performance highlights his importance to the team.
The occurrence of blood clots among NBA players like Lillard and Wembanyama raises concerns within the league. This season has seen an unprecedented number of such cases over the past decade.